Clinical use of progesterone in human sperm preparation media for increasing IVF success
Rattachement africain : au. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
RESEARCH QUESTION: Can the addition of progesterone and neurotensin, molecular agents found in the female reproductive tract, after sperm washing increase the fertilization potential of human spermatozoa? DESIGN: (i) Cohort study of 24 men. Spermatozoa selected by swim-up were incubated in either progesterone or neurotensin (0.1-100 µM) for 1-4 h, and hyperactive motility and binding to hyaluronan (0.1-100 µM) were assessed. The effect of progesterone 10 µM on sperm function was assessed in a blinded manner, including: hyperactive motility, binding to hyaluronan, tyrosine phosphorylation, acrosome reaction and oxidative DNA damage. (i) Embryo safety testing [one-cell mouse embryo assay (MEA), endotoxin and sterility counts (n = 3)] in preclinical embryo models of IVF (murine and porcine, n = 7 each model) and a small preliminary human study (n = 4) of couples undergoing standard IVF with oocytes inseminated with spermatozoa ± 10 µM progesterone. RESULTS: Progesterone 10 µM increased sperm binding to hyaluronan, hyperactive motility and tyrosine phosphorylation (all P < 0.05). Neurotensin had no effect (P > 0.05). Progesterone 10 µM in human embryo culture media passed embryo safety testing (MEA, endotoxin concentration and sterility plate count). In preclinical models of IVF, the exposure of spermatozoa to progesterone 10 µM and oocytes to progesterone 1 µM was not detrimental, and increased the fertilization rate in mice and the blastocyst cell number in mice and pigs (all P ≤ 0.03). In humans, every transferred blastocyst that had been produced from spermatozoa exposed to progesterone resulted in a live birth. CONCLUSION: The addition of progesterone to sperm preparation media shows promise as an adjunct to current methods for increasing fertilization potential. Randomized controlled trials are required to determine the clinical utility of progesterone for improving IVF outcomes.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Clinical use of progesterone in human sperm preparation media for increasing IVF success
- Date Crossref
- 01/04/2024
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Monash IVF pays non établi dans la noticeÉtablissement de santé
-
Freemasons Foundation Centre for Men's Health pays non établi dans la noticeInstitution
-
The University of Adelaide Freemasons Centre for Male Health and Wellbeing pays non établi dans la noticeUniversité ou école supérieure
-
Monash University pays non établi dans la noticeUniversité ou école supérieure
-
University of Newcastle Australia Australia pays non établi dans la noticeUniversité ou école supérieure
-
School of Biomedicine Discipline of Reproduction and Development pays non établi dans la noticeUniversité ou école supérieure
-
Repromed pays non établi dans la noticeInstitution
-
Memphasys Ltd pays non établi dans la noticeEntreprise
Monash IVF, Freemasons Foundation Centre for Men's Health et Freemasons Centre for Male Health and Wellbeing — The University of Adelaide, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.